DonaldZozMDFCCP

Pulmonology • Lebanon, OH

Interstitial Lung Diseases

Sr. Clinical Program Leader - IPF/ILD Boehringer Ingelheim

Join to view full profile

Dr. Zoz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zoz's full profile

Already have an account?

Office
Remote
Lebanon, OH 45036

Education & Training

Vanderbilt University Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2008 - 2011
Ohio State University HospitalResidency, Internal Medicine, 2005 - 2008
Ohio State University College of MedicineClass of 2005

Certifications & Licensure

OH State Medical License 2006 - 2025
TN State Medical License 2008 - 2011
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013

Clinical Trials

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
Terminated
Phase 2
Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection Start of enrollment: 2014 Jun 09
Completed
Phase 2
Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment Start of enrollment: 2016 Jun 09
Completed
Phase 4
Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment Start of enrollment: 2016 Jun 30
Completed
Phase 3
Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications Start of enrollment: 2017 Jan 11
Completed
Phase 3
A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza Start of enrollment: 2016 Dec 08
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

7 citations
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF).
Luca Richeldi, Arata Azuma, Vincent Cottin, Michael Kreuter, Toby M Maher
BMJ Open Respiratory Research. 2023-08-01
11 citations
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease.
David Roofeh, Kevin K Brown, Ella A Kazerooni, Donald Tashkin, Shervin Assassi
Rheumatology. 2023-05-02
2 citations
Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptations.
Steve Jones, Maxine Flewett, Ron Flewett, Sharon Lee, Bill Vick
ERJ Open Research. 2023-05-01

Press Mentions

First Patient Enrolled in Phase 3 Trial Testing BI 1015550October 28th, 2022
Boehringer Enrols First Subject in Idiopathic Pulmonary Fibrosis TrialOctober 27th, 2022
Systemic Sclerosis (Scleroderma): Nintedanib Slowed Loss of Pulmonary FunctionMay 30th, 2019

Professional Memberships

American Thoracic Society - ATS
Member
American College of Chest Physicians - ACCP
Fellow

Industry Relationships

Director - Clinical Development & Medical Affairs - Respiratory IPF/ILD, Boehringer Ingelheim Pharmaceuticals, Inc2017 - Present